This company listing is no longer active
CX5 Stock Overview
A biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LadRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.056 |
| 52 Week High | US$21.80 |
| 52 Week Low | US$0.056 |
| Beta | 1.71 |
| 1 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| CX5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 2.3% |
| 1Y | -99.4% | -5.6% | 16.7% |
Return vs Industry: CX5 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: CX5 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| CX5 volatility | |
|---|---|
| CX5 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CX5's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CX5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 3 | Stephen Snowdy | www.ladrxcorp.com |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company’s Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer.
LadRx Corporation Fundamentals Summary
| CX5 fundamental statistics | |
|---|---|
| Market cap | €905.08k |
| Earnings (TTM) | -€4.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs CX5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CX5 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.40m |
| Earnings | -US$4.40m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CX5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/14 10:27 |
| End of Day Share Price | 2023/05/17 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LadRx Corporation is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashok Kumar | Aegis Capital Corporation |
| Jonathan Aschoff | Brean Capital |
| Christopher James | FBR Capital Markets & Co. |